Samsung Biologics Co Ltd (207940.KS)
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and regulatory support services; and quality, biosafety and analytical testing services, as well as manufactures drug substance. In addition, it engages in the development and commercialization of biosimilar drugs; development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Company Info
Highlights
₩73.45T
2.37
₩4.90T
₩2.60T
₩722,000.00 - ₩1,000,000.00
₩1,000,000.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Samsung Biologics Co Ltd (207940.KS) returned 5.37% year-to-date (YTD) and 36.99% over the past 12 months.
207940.KS
5.37%
-0.00%
2.56%
36.99%
5.69%
10.19%
N/A
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 207940.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5.37% | 0.00% | 0.00% | -0.00% | -0.00% | 5.37% | |||||||
| 2024 | 10.53% | -7.86% | 7.36% | -6.02% | -6.53% | -0.41% | 29.02% | 4.48% | -0.31% | 2.35% | -2.50% | -2.67% | 24.87% |
| 2023 | -3.29% | -2.64% | 1.94% | -0.89% | 0.38% | -5.10% | 2.96% | -3.79% | -7.60% | 4.11% | 2.26% | 4.83% | -7.43% |
| 2022 | -18.16% | 4.06% | 8.68% | 1.33% | 1.07% | -6.73% | 9.49% | -3.47% | -3.35% | 8.67% | 1.14% | -7.44% | -8.12% |
| 2021 | -4.00% | -5.42% | -0.27% | 7.49% | 5.10% | -0.47% | 5.83% | 8.43% | -9.43% | -0.34% | 2.07% | 1.57% | 9.32% |
| 2020 | 11.89% | -4.33% | 3.99% | 20.54% | 7.06% | 24.60% | -5.42% | 6.14% | -11.31% | -1.16% | 15.25% | 5.09% | 90.76% |
| 2019 | 3.23% | -5.76% | -15.03% | 6.42% | -11.76% | 6.67% | -12.50% | -3.93% | 14.31% | 29.59% | -1.25% | 10.04% | 12.03% |
| 2018 | 18.19% | 2.62% | 8.22% | 0.21% | -10.86% | -4.14% | -10.55% | 24.13% | 15.33% | -27.43% | -13.68% | 15.55% | 4.18% |
| 2017 | 6.62% | 2.17% | 5.17% | 1.16% | 25.71% | 32.73% | -6.85% | 4.04% | 19.26% | 13.78% | -10.81% | 8.32% | 145.70% |
| 2016 | -4.64% | -1.95% | -6.50% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 89, 207940.KS is among the top 11% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Samsung Biologics Co Ltd (207940.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Samsung Biologics Co Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Samsung Biologics Co Ltd was 57.28%, occurring on Aug 7, 2019. Recovery took 175 trading sessions.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -57.28% | Apr 12, 2018 | 324 | Aug 7, 2019 | 175 | Apr 23, 2020 | 499 |
| -32% | Aug 18, 2021 | 520 | Sep 26, 2023 | — | — | — |
| -25.27% | Aug 13, 2020 | 48 | Oct 26, 2020 | 30 | Dec 7, 2020 | 78 |
| -22.16% | Dec 8, 2020 | 61 | Mar 10, 2021 | 46 | May 14, 2021 | 107 |
| -19.09% | Nov 15, 2016 | 14 | Dec 2, 2016 | 70 | Mar 16, 2017 | 84 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Samsung Biologics Co Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Samsung Biologics Co Ltd, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 31.3% positive surprise.
Valuation
The Valuation section provides an overview of how Samsung Biologics Co Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 207940.KS compared to other companies in the Biotechnology industry. 207940.KS currently has a PEG ratio of 2.4. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 207940.KS relative to other companies in the Biotechnology industry. Currently, 207940.KS has a P/S ratio of 15.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 207940.KS in comparison with other companies in the Biotechnology industry. Currently, 207940.KS has a P/B value of 6.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |